JPMorgan Starts ConforMIS (CFMS) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Bel Fuse acquires dataMate ethernet business for $16 million
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
UPDATE: Oppenheimer Starts ConforMIS (CFMS) at Outperform
July 27, 2015 7:40 AM EDT(Updated - July 27, 2015 9:12 AM EDT)
Oppenheimer initiated coverage on ConforMIS (NASDAQ: CFMS) with an Outperform rating and a price target of $26.
Analyst Steven Lichtman said, "CFMS's unique iFit technology provides custom implants designed to match the individual anatomy of a patient undergoing total... More
Wells Fargo Starts ConforMIS (CFMS) at Outperform
July 27, 2015 7:38 AM EDTWells Fargo initiated coverage on ConforMIS (NASDAQ: CFMS) with an Outperform rating.
For an analyst ratings summary and ratings history on ConforMIS click here. For more ratings news on ConforMIS click here.
Shares of ConforMIS closed at $22.12 yesterday.
... MoreUPDATE: Canaccord Genuity Starts ConforMIS (CFMS) at Buy
July 27, 2015 7:37 AM EDT(Updated - July 27, 2015 8:47 AM EDT)
Canaccord Genuity initiated coverage on ConforMIS (NASDAQ: CFMS) with a Buy rating and a price target of $27.00.
Analyst William J. Plovanic said, "We believe ConforMIS is a disruptive technology in the multi-billion dollar global orthopedic implant market.... More
Deutsche Bank Starts ConforMIS (CFMS) at Buy
July 27, 2015 7:36 AM EDTDeutsche Bank initiated coverage on ConforMIS (NASDAQ: CFMS) with a Buy rating and a price target of $27.
Analyst Kristen Stewart said, "ConforMIS is an orthopedic manufacturer of fully customized implants utilizing its iFit technology--iFit design, iFit printing (3D printing), and iFit just-in-time... More
